Vifor Builds Its Kidney Disease Focus With $80m Angion Deal

Novel Drug Targets Two Kidney Injury Conditions

Deal helps Vifor pursue goal of becoming a leader in kidney disease therapies.

Kidneys
Vifor is on the hunt for new licensing deals, especially in nephrology, where it aims to be a market leader.

Vifor Pharma has struck a licensing deal worth up to $80m with Angion Biomedica for its novel candidate for patients with acute kidney injury, ANG-3777, currently in Phase III trials.

ANG-3777 is being developed for treatment of two kidney conditions, delayed graft function and cardiac surgery-associated acute kidney injury.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip